Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 2;7(31):50417-50427.
doi: 10.18632/oncotarget.10413.

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

Tengyun Wu  1 , Wei Zhang  2 , Geliang Yang  3 , Huijun Li  4 , Qi Chen  5 , Ruixiang Song  2 , Lin Zhao  2
Affiliations
Review

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

Tengyun Wu et al. Oncotarget. .

Abstract

As there are millions of cancer deaths every year, it is of great value to identify applicable prognostic biomarkers. As an important alarm, the prognostic role of high mobility group box 1 (HMGB1) in cancer remains controversial. We aim to assess the association of HMGB1 expression with prognosis in cancer patients. Systematic literature searches of PubMed, Embase and Web of Science databases were performed for eligible studies of HMGB1 as prognostic factor in cancer. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the influence of HMGB1 expression on overall survival (OS) and progression-free survival (PFS) in cancer patients. 18 studies involving 11 different tumor types were included in meta-analysis. HMGB1 overexpression was significantly associated with poorer OS (HR: 1.99; 95% CI, 1.71-2.31) and PFS (HR: 2.26; 95% CI, 1.65-3.10) irrespective of cancer types including gastric cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, nasopharyngeal carcinoma, head and neck squamous-cell carcinoma, esophageal cancer, malignant pleural mesothelioma, bladder cancer, prostate cancer, and cervical carcinoma. Subgroup analyses indicated geographical area and size of studies did not affect the prognostic effects of HMGB1 for OS. Morever, HMGB1 overexpression had a consistent correlation with poorer OS when detected by immunohistochemistry in tissues and enzyme-linked immunosorbent assay in serum, whereas the correlation did not exist by quantitative real-time reverse-transcription polymerase chain reaction in tissues. HMGB1 overexpression is associated with poorer prognosis in patients with various types of cancer, suggesting that it is a prognostic factor and potential biomarker for survival in cancer.

Keywords: cancer; high mobility group box 1; meta-analysis; prognosis factor; survival.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1. Flow diagram of search strategy
Figure 2
Figure 2. Forest plot evaluating association of HMGB1 expression and overall survival
Figure 3
Figure 3. Subgroup forest plot evaluating association of HMGB1 expression and overall survival by specimen source and detection method
Figure 4
Figure 4. Subgroup forest plot evaluating association of HMGB1 expression and overall survival by geographical area
Figure 5
Figure 5. Subgroup forest plot evaluating association of HMGB1 expression and overall survival by size of studies
Figure 6
Figure 6. Forest plot evaluating association of HMGB1 expression and progression-free survival
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. World Health Organization. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx Website: Accessed September 27, 2015. - PubMed
    1. Zhao H, Guo L, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6:5022–5040. doi: 10.18632/oncotarget.3217. - DOI - PMC - PubMed
    1. Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacology & therapeutics. 2015 - PubMed
    1. Goodwin GH, Johns EW. Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids. European journal of biochemistry / FEBS. 1973;40:215–219. - PubMed
    1. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–251. - PubMed